

PATENT
454313-2335.1


AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents. Attached is a marked up version of the amended claims entitled "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

IN THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

12. (Amended) An immunogenic preparation comprising a complex of: at least one plasmid encoding and expressing *in vivo* in a porcine host an isolated nucleic acid molecule selected from the group consisting of open reading frame (ORF) 1 of porcine circovirus type II (PCV-2) and ORF2 of PCV-2; and, an adjuvant which comprises a cationic lipid of formula



in which R₁ is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R₂ is aliphatic radical comprising from 2 to 3 carbon atoms, and X is an hydroxyl or amine group.


13. (Amended) An immunogenic preparation comprising at least one plasmid encoding and expressing *in vivo* in a porcine host an isolated nucleic acid molecule selected from the group consisting of open reading frame (ORF) 1 of porcine circovirus type II (PCV-2) and ORF2 of PCV-2; and, an adjuvant comprising a carbomer.

20. (Twice Amended) The immunogenic preparation according to claim 12 or 13, further comprising a plasmid encoding and expressing an immunogen from a porcine pathogenic agent other than PCV-2.

PATENT
454313-2335.1

e3 24. (Twice Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least two plasmids, one that contains and expresses ORF1 of PCV-2, and one that contains and expresses ORF2 of PCV-2.

e4 40. (Amended) A method for enhancing a host immune response, in a porcine host, to a polypeptide encoded by open reading frame (ORF) 1 of porcine circovirus type II (PCV-2) or ORF2 of PCV-2, said method comprising administering to the porcine host at least one plasmid that encodes and expresses ORF1 of PCV-2 or ORF2 of PCV-2, wherein the plasmid is complexed with an adjuvant which comprises a cationic lipid of formula



in which R₁ is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R₂ is aliphatic radical comprising from 2 to 3 carbon atoms, and X is an hydroxyl or amine group.

41. (Amended) A method for enhancing a host immune response, in a porcine host, to a polypeptide encoded by open reading frame (ORF) 1 of porcine circovirus type II (PCV-2) or ORF2 of PCV-2, said method comprising administering to the porcine host at least one plasmid that encodes and expresses ORF1 of PCV-2 or ORF2 of PCV-2, and an adjuvant which comprises a carbomer.

e5 47. (Amended) The method according to claim 40 or 41, wherein the administering includes administering a plasmid encoding and expressing an immunogen from a porcine pathogenic agent other than PCV-2.

e6 51. (Amended) The method according to any one of claims 40 or 41, wherein the administering includes administering at least two plasmids, one that contains and expresses ORF1 of PCV-2, and one that contains and expresses ORF2 of PCV-2.

PATENT
454313-2335.1

Please cancel claims 25, 26, 52, 53, 67 and 68 without prejudice, without admission,
without surrender of subject matter and without any intention of creating estoppel as to
equivalents.